Long-term survival after ovarian cancer diagnosis higher than previously thought
the ONA take:
UC Davis researchers reviewed data collected on thousands of patients with ovarian cancer in California and found that survival rates are higher than predicted for most women. In fact, almost one-third of patients survive at least 10 years after diagnosis.
The study confirmed the factors associated with higher survival, such as younger age, early stage, and lower grade tumor at diagnosis; however, it also found a surprising number of survivors who did not meet that criteria. Most survival studies consider 5-year survival or less; this study looked at 10-year survival.
Of the 11,541 patients in the California Cancer Registry, the database used for the study, 3,582 survived more than 10 years. Furthermore, 954 of those survivors had been considered to be at high risk of dying from their disease.
The researchers’ next step is to figure why so many women who are given a poor prognosis beat their odds. Some theories include women with the BRCA1/2 mutation may respond better to chemotherapy, biological differences in women may affect individual outcomes, or some patients may receive more effective treatment than others.
Survival rates for ovarian cancer are higher than predicted for most women.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|